Abstract. 4A syndrome is characterised by adrenocortical insufficiency, achalasia, alacrima, autonomic and other neurological abnormalities. We report an 18-year-old boy with 4 A syndrome and having all classical features of the disease including sensorimotor neuropathy.
FAMILIAL
glucocorticoid deficiency associated with achalasia of the cardia and deficient tear production was described in 1978 by Allgrove et al. [1] . Since then a number of similar cases have been reported in the literature [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Triple A syndrome; characterised by adrenal insufficiency, achalasia and alacrima, is a rare disorder.
Only 61 families with 92 patients have so far been described. Motor and sensory neuropathy have also been described, indicating that the disorder has a wide spectrum of clinical manifestations [10, 12, 13] . 4A syndrome (including autonomic neuropathy to triple A syndrome) was first described by Gazarian et al. in 1995 [14] . [8] and unusual f acies [8] .
The disorder is usually inherited in an autosomal recessive pattern and it has been shown to be associated with a GTP binding protein-linked hormone receptor mutation [16] .
We present an 18-year-old white male with alacrima, achalasia, adrenocortical insufficiency, neurologic abnormalities and a not well-known feature, osteoporosis (Fig. 1) .
Case Report There is one healthy sibling. His weight was 44 kg (< 5th percentile), height was 165 cm (5th percentile), pulse was 100/ min and blood pressure was 90/60 mmHg. The patient was malnourished and darkly pigmented, with particular darkening of the elbows, knees, nipples, palmar creases and buccal mucosa. There was bilateral pes cavus and flexion contractor in his hands.
Schirmer test revealed alacrima. Neurological examination revealed sensorimotor neuropathy.
According to WAIS-R findings his total IQ score was 91. His sexual maturity was associated with Tanner stage 5 and his bone age was associated with 17 years old.
Thyroid, renal and hepatic function tests, serum FSH, LH, PRL, GH, free and total testosterone levels were all within normal limits. (1.5 ug/dl) and after ACTH stimulation, at 30, 60 and 90 min, the cortisol level was not changed (41.38 nmol/L). The peak GH response to L-Dopa stimulation was normal (11 ug/L). Electomyographic and nerve conduction studies indicated a sensorimotor neuropathy in the lower extremities.
Bone mineral content (BMC) and bone mineral density (BMD) was assessed by dual X-ray absorptiometry (Hologic QDR 4500-A). BMD and BMC scores are shown in A similar neuropathic process presumably underlies the oesophageal dysmotility and impaired bladder function. Radionuclide methods are being increasingly used to study gastric and bladder emptying and by these means disorders of autonomic neuropathy can be shown [17] . Assessing gastric and bladder emptying is valuable in the diagnosis of autonomic neuropathy and performing one of them, provides information on the other [18] . It was found that in normal subjects mean t1,'2 for bladder emptying was 23.24 ± 1.8 sec [18] . This patient's t1,'2 for bladder emptying was 34 sec. After all the secondary causes were excluded this prolongation was attributed to autonomic neuropathy. Low renin levels may also be attributable to autonomic dysfunction.
Glucococorticoid receptors are ubiquitous and glucocorticoid action varies from cell to cell. In invitro studies, glucocorticoids suppress or increase osteoblast proliferation depending on the state of maturation of the cells and the species [19, 20] . In culture studies, glucocorticoids have two additional effects: they increase sensitivity to parathyroid hormone and stimulate osteoblastic differentiation. Glucocorticoids were shown to increase the number of PTH receptors as well as the abundance of G proteins, which mediate PTH stimulation of adenylate cyclase [21] . The effect of glucocorticoids on the expression of osteoblastic features could reflect the requirement of this hormone for osteoblast differentiation.
Glucocorticoids were shown to increase the expression of alkaline phosphatase in osteoblastic tumour cells [22] . 
